Claritev (NYSE:CTEV - Get Free Report) major shareholder Ares Management Llc purchased 13,587 shares of Claritev stock in a transaction that occurred on Wednesday, November 11th. The stock was acquired at an average cost of $28.73 per share, with a total value of $390,354.51. Following the acquisition, the insider directly owned 2,063,105 shares in the company, valued at $59,273,006.65. This trade represents a 0.66% increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Major shareholders that own more than 10% of a company's shares are required to disclose their sales and purchases with the SEC.
Ares Management Llc also recently made the following trade(s):
- On Tuesday, November 10th, Ares Management Llc purchased 65,579 shares of Claritev stock. The shares were acquired at an average price of $26.14 per share, for a total transaction of $1,714,235.06.
- On Monday, November 9th, Ares Management Llc acquired 50,000 shares of Claritev stock. The stock was acquired at an average cost of $24.42 per share, for a total transaction of $1,221,000.00.
- On Monday, October 26th, Ares Management Llc acquired 20,834 shares of Claritev stock. The stock was acquired at an average cost of $24.07 per share, for a total transaction of $501,474.38.
- On Friday, October 23rd, Ares Management Llc acquired 50,000 shares of Claritev stock. The stock was acquired at an average price of $23.53 per share, with a total value of $1,176,500.00.
Claritev Stock Down 6.7%
Shares of Claritev stock traded down $1.80 on Monday, reaching $25.02. The company's stock had a trading volume of 152,295 shares, compared to its average volume of 312,186. The stock has a 50-day moving average price of $26.18 and a 200-day moving average price of $25.46. Claritev has a 52-week low of $11.50 and a 52-week high of $55.50.
Claritev (NYSE:CTEV - Get Free Report) last announced its earnings results on Monday, November 9th. The company reported $1.77 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($3.68) by $5.45. The business had revenue of $268.31 million for the quarter. On average, analysts anticipate that Claritev will post -15.02 EPS for the current fiscal year.
Institutional Inflows and Outflows
Hedge funds have recently added to or reduced their stakes in the company. Entropy Technologies LP acquired a new stake in shares of Claritev in the third quarter valued at about $265,000. Marshall Wace LLP grew its stake in Claritev by 1,569.2% during the 3rd quarter. Marshall Wace LLP now owns 225,890 shares of the company's stock valued at $4,782,000 after acquiring an additional 212,357 shares in the last quarter. Engineers Gate Manager LP purchased a new stake in Claritev during the 2nd quarter valued at about $245,000. Integrated Wealth Concepts LLC acquired a new stake in Claritev in the 2nd quarter valued at about $44,000. Finally, Public Investment Fund acquired a new stake in Claritev in the 2nd quarter valued at about $43,703,438. 87.15% of the stock is owned by institutional investors and hedge funds.
Wall Street Analyst Weigh In
CTEV has been the topic of several recent analyst reports. Canaccord Genuity Group increased their price objective on shares of Claritev from $37.00 to $43.00 and gave the company a "buy" rating in a report on Monday, August 10th. Weiss Ratings reissued a "sell (d-)" rating on shares of Claritev in a research note on Monday, September 21st. Piper Sandler restated an "overweight" rating and set a $73.00 price target on shares of Claritev in a research report on Wednesday, August 12th. Wall Street Zen raised shares of Claritev from a "sell" rating to a "hold" rating in a research note on Saturday, August 8th. Finally, Barclays reiterated an "overweight" rating and issued a $40.00 price objective (up from $28.00) on shares of Claritev in a report on Thursday, August 20th. Six research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, Claritev has a consensus rating of "Moderate Buy" and an average target price of $44.83.
Get Our Latest Stock Analysis on Claritev
About Claritev
(
Get Free Report)
Claritev, formerly known as MultiPlan, provides technology-enabled services intended to help manage healthcare costs and support payment accuracy. Its offerings include access to provider networks, claims and payment solutions, and data analytics for evaluating healthcare costs and utilization. The company serves health plans, self-insured employers, third-party administrators and other participants in the U.S. healthcare system. Its services are designed to help customers identify cost-management opportunities and support more efficient healthcare transactions.
Read More

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Claritev, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Claritev wasn't on the list.
While Claritev currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.